These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

500 related articles for article (PubMed ID: 33249937)

  • 1. Salvage systemic therapy for metastatic urothelial carcinoma: an unmet clinical need.
    Montazeri K; Sonpavde G
    Expert Rev Anticancer Ther; 2021 Mar; 21(3):299-313. PubMed ID: 33249937
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Erdafitinib for the treatment of metastatic bladder cancer.
    Montazeri K; Bellmunt J
    Expert Rev Clin Pharmacol; 2020 Jan; 13(1):1-6. PubMed ID: 31810398
    [No Abstract]   [Full Text] [Related]  

  • 3. Current Therapy for Metastatic Urothelial Carcinoma.
    Nadal R; Clara JA; Valderrama BP; Bellmunt J
    Hematol Oncol Clin North Am; 2021 Jun; 35(3):469-493. PubMed ID: 33958146
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of metastatic urothelial carcinoma: Current approach, emerging agents, and future perspectives.
    Iacovelli R; Cicala CM; Ciccarese C; Sacco E; Racioppi M; Bassi PF; Tortora G
    Urologia; 2023 Feb; 90(1):3-10. PubMed ID: 36537831
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Rapidly Evolving Landscape of First-Line Targeted Therapy in Metastatic Urothelial Cancer: A Systematic Review.
    Lavoie JM; Sridhar SS; Ong M; North S; Alimohamed N; McLeod D; Eigl BJ
    Oncologist; 2021 Aug; 26(8):e1381-e1394. PubMed ID: 34028134
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted Molecular Therapeutics for Bladder Cancer-A New Option beyond the Mixed Fortunes of Immune Checkpoint Inhibitors?
    Bednova O; Leyton JV
    Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33019653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Urothelial carcinoma: the development of FGFR inhibitors in combination with immune checkpoint inhibitors.
    Qin Q; Patel V; Galsky MD
    Expert Rev Anticancer Ther; 2020 Jun; 20(6):503-512. PubMed ID: 32436413
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The management of toxicities from immune, targeted and ADCs treatments in patients with urothelial cancer.
    Atiq S; Hirshman N; Shariff A; Zhang T
    Urol Oncol; 2023 Oct; 41(10):410-419. PubMed ID: 34973855
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and toxicity of antibody-drug conjugates in the treatment of metastatic urothelial cancer: A scoping review.
    Padua TC; Moschini M; Martini A; Pederzoli F; Nocera L; Marandino L; Raggi D; Briganti A; Montorsi F; Necchi A
    Urol Oncol; 2022 Oct; 40(10):413-423. PubMed ID: 35973928
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biomarker-Oriented Therapy in Bladder and Renal Cancer.
    Scholtes MP; Alberts AR; Iflé IG; Verhagen PCMS; van der Veldt AAM; Zuiverloon TCM
    Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33799514
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genomic Profiling and Molecular Characterisation of Metastatic Urothelial Carcinoma.
    Pezzicoli G; Ciciriello F; Musci V; Minei S; Biasi A; Ragno A; Cafforio P; Rizzo M
    Medicina (Kaunas); 2024 Mar; 60(4):. PubMed ID: 38674231
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Durvalumab in urothelial cancers.
    Lavaud P; Hamilou Z; Loriot Y; Massard C
    Expert Rev Anticancer Ther; 2018 Apr; 18(4):311-318. PubMed ID: 29486607
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overview of the clinical use of erdafitinib as a treatment option for the metastatic urothelial carcinoma: where do we stand.
    D'Angelo A; Bagby S; Galli IC; Bortoletti C; Roviello G
    Expert Rev Clin Pharmacol; 2020 Oct; 13(10):1139-1146. PubMed ID: 32935605
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Durable Response to Enfortumab Vedotin Compared to Re-challenging Chemotherapy in Metastatic Urothelial Carcinoma After Checkpoint Inhibitors.
    Uchimoto T; Tsuchida S; Komura K; Fukuokaya W; Adachi T; Hirasawa Y; Hashimoto T; Yoshizawa A; Saruta M; Hashimoto M; Higashio T; Matsuda T; Nishimura K; Tsujino T; Nakamura K; Fukushima T; Nishio K; Yamamoto S; Iwatani K; Urabe F; Mori K; Yanagisawa T; Tsuduki S; Takahara K; Inamoto T; Miki J; Fujita K; Kimura T; Ohno Y; Shiroki R; Uemura H; Azuma H
    Target Oncol; 2024 May; 19(3):401-410. PubMed ID: 38546942
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of Targeted Therapies in Management of Metastatic Urothelial Cancer in the Era of Immunotherapy.
    Grivas P; Yu EY
    Curr Treat Options Oncol; 2019 Jun; 20(8):67. PubMed ID: 31254108
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Overview of Enfortumab Vedotin in the Management of Locally Advanced or Metastatic Urothelial Carcinoma.
    Hanna KS
    Drugs; 2020 Jan; 80(1):1-7. PubMed ID: 31823332
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enfortumab Vedotin, a fully human monoclonal antibody against Nectin 4 conjugated to monomethyl auristatin E for metastatic urothelial Carcinoma.
    McGregor BA; Sonpavde G
    Expert Opin Investig Drugs; 2019 Oct; 28(10):821-826. PubMed ID: 31526130
    [No Abstract]   [Full Text] [Related]  

  • 18. Emerging drugs for urothelial (bladder) cancer.
    Cumberbatch K; He T; Thorogood Z; Gartrell BA
    Expert Opin Emerg Drugs; 2017 Jun; 22(2):149-164. PubMed ID: 28556678
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The 27-gene IO score is associated with efficacy of PD-1/L1 inhibitors independent of FGFR expression in a real-world metastatic urothelial carcinoma cohort.
    Nielsen TJ; Varga MG; Cronister CT; Ring BZ; Seitz RS; Ross DT; Schweitzer BL; McGregor K
    Cancer Immunol Immunother; 2023 Jul; 72(7):2075-2086. PubMed ID: 36806983
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biomarkers of Response to Anti-NECTIN4 Antibody-Drug Conjugate Enfortumab Vedotin in Urothelial Cancer.
    Klümper N; Eckstein M
    Eur Urol Focus; 2024 Mar; 10(2):224-226. PubMed ID: 38631991
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.